Iminopyrimidinones: a novel pharmacophore for the development of orally active renin inhibitors.
McKittrick, B.A., Caldwell, J.P., Bara, T., Boykow, G., Chintala, M., Clader, J., Czarniecki, M., Courneya, B., Duffy, R., Fleming, L., Giessert, R., Greenlee, W.J., Heap, C., Hong, L., Huang, Y., Iserloh, U., Josien, H., Khan, T., Korfmacher, W., Liang, X., Mazzola, R., Mitra, S., Moore, K., Orth, P., Rajagopalan, M., Roy, S., Sakwa, S., Strickland, C., Vaccaro, H., Voigt, J., Wang, H., Wong, J., Zhang, R., Zych, A.(2015) Bioorg Med Chem Lett 25: 1592-1596
- PubMed: 25728416 
- DOI: 10.1016/j.bmcl.2015.02.003
- Primary Citation of Related Structures:  
4S1G, 4XX3, 4XX4 - PubMed Abstract: 
The development of renin inhibitors with favorable oral pharmacokinetic profiles has been a longstanding challenge for the pharmaceutical industry. As part of our work to identify inhibitors of BACE1, we have previously developed iminopyrimidinones as a novel pharmacophore for aspartyl protease inhibition ...